It's time for the big three. We've got three stocks, three charts, three trades. Rick Ducat will take us through the charts.And here to take us through his picks today, Tim Bowen, chief technical trainer for stockstotrade. com. Great to see you both.Tim, as always, let's kick things off with a big picture thought on the market this week. >> Yeah. Well, obviously not what we want to see.Uh, you know, the viewers know, you guys know I'm very bullish. AI technology, you know, all of this stuff from a lifelong ...

公司概况 - 公司为专注于肾脏疾病疗法研发和商业化的生物制药公司，总部位于马萨诸塞州剑桥 [1] - 公司在生物制药行业面临其他开发类似疗法公司的竞争 [1] 近期业绩与事件 - 公司计划于2025年11月10日公布季度财报，并将于美国东部时间上午8:00举行电话会议讨论业绩和近期业务亮点 [2] - 华尔街预计公司每股收益为-0.02美元，预计营收约为5820万美元 [2] 估值指标 - 公司市盈率为负值-14.47，市销率约为2.62，即投资者为其每美元销售额支付2.62美元 [3] - 企业价值与销售额比率约为2.20，企业价值与营运现金流比率显著为负，约为-186.85 [3][4] - 收益率为负值，约为-6.91% [4] 财务健康状况 - 公司债务与股东权益比率为1.83，表明债务水平相对较高 [5] - 流动比率约为1.98，表明流动资产几乎是流动负债的两倍，短期财务健康状况尚可 [5]

New York, NY, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Following a challenge submitted by Pfizer, Inc., BBB National Programs’ National Advertising Division will refer BridgeBio Pharma Inc. to the relevant government agencies for review and possible enforcement action for failure to participate in the National Advertising Division (NAD) inquiry. Pfizer and BridgeBio sell prescription medication to treat transthyretin amyloid cardiomyopathy, a progressive and fatal disease caused by the buildup of a protein called ...

Block (XYZ) shares slumped Friday after the fintech company's quarterly results fell short of Wall Street's expectations on the top and bottom lines. Shares of payments provider Block have lost about one-quarter of their value in 2025. Al Drago / Bloomberg / Getty Images Close Key Takeaways The stock was down about 10% in recent trading, leading decliners in the S&P 500. Read Investopedia's full daily markets coverage here. Block reported adjusted earnings of 54 cents a share on revenue that rose about ...

Intel's stock has surged over 85% in 2025 so far. David Paul Morris / Bloomberg / Getty Images, Matthias Balk / dpa / Getty Images Close Key Takeaways After a string of recent high-profile deals for Intel, could one with Tesla be next? The question became inevitable after Tesla (TSLA) CEO Elon Musk told investors at the electric vehicle maker's shareholder meeting yesterday that the company, which has increasingly shifted its focus on AI and robotics, would need a "gigantic" semiconductor fabrication plant ...

This week was brutal for leading artificial intelligence stocks, with Nvidia Corp. (NASDAQ:NVDA), Palantir Technologies, Inc. (NASDAQ:PLTR), and Advanced Micro Devices, Inc. (NASDAQ:AMD) all suffering their steepest declines in months amid growing market chatter about an "AI bubble."Investors who piled into the sector earlier this year began taking profits as valuations stretched and sentiment shifted toward caution.NVDA stock is dropping. Watch the price action here. PLTR's Earnings BurnPalantir posted its ...

Meta Platforms on Friday said it will invest $600 billion in U.S. infrastructure and jobs over the next three years, including artificial intelligence data centers, as the social media giant races to ... ...

The U.S. Food and Drug Administration (FDA) approved on Thursday Johnson & Johnson’s (NYSE:JNJ) Darzalex Faspro (daratumumab and hyaluronidase-fihj) for a type of blood cancer.Darzalex Faspro is the first and only approved treatment for high-risk smoldering multiple myeloma (HR-SMM), enabling earlier intervention before the disease progresses to active multiple myeloma.Smoldering multiple myeloma is an asymptomatic (no signs or symptoms) precursor state of active myeloma.FDA approval is based on findings fr ...

Rivian Automotive, Inc. (NASDAQ:RIVN) shares slipped Friday as investors weighed mixed signals following the company’s third-quarter update.RIVN is among today’s weakest performers. Check the full analysis hereMomentum has cooled despite strong growth, with Wall Street parsing comments about future scale and cash needs.On November 4, the EV company announced third-quarter total revenue of $1.56 billion, representing an 78% year-over-year increase, surpassing the Street consensus estimate of $1.50 billion.Al ...

Key Takeaways Insperity posted a Q3 adjusted loss of $0.20 per share, missing expectations for a $0.22 profit.Q3 revenue rose 4% to $1.6B, but lower margins pushed gross profit down 15% year over year.The firm cut its 2025 EPS outlook to $0.84-$1.47 and trimmed adjusted EBITDA guidance to $119-$153M.Insperity, Inc. (NSP) reported lower-than-expected third-quarter 2025 results.The stock has declined 22.8% since the earnings release on Nov. 3 in response to dismal earnings and revenues, and a weak EPS guidanc ...